Inhibition of Rho modulates cytokine-induced prostaglandin E2 formation in renal mesangial cells.
Stimulation of rat mesangial cells for 24 h with interleukin-1beta (IL- 1beta) plus forskolin (Fk) leads to a marked increase in prostaglandin E2 (PGE2) synthesis. This effect is further enhanced by the small G-protein Rho inhibitor toxin A. A similar increase in PGE2 formation is obtained with Y27632, a Rho-dependent kinase inhibitor, and with lovastatin, a hydroxymethylglutaryl-coenzyme A inhibitor which depletes cells from geranylgeranyl moieties and thus blocks Rho activation. In parallel to the increased PGE2 synthesis, a potentiation of IL-1beta-induced secretory group IIA phospholipases A2 (sPLA2-IIA) protein expression also occurs by Rho inhibition. However, only toxin A triggers an increased sPLA2-IIA activity consistent with the elevated levels of protein expression, whereas Y27632 and lovastatin rather reduced IL-1beta-induced sPLA2-IIA activity. In vitro activity studies reveal that Y27632 and lovastatin can directly block sPLA2-IIA enzyme activity in a concentration-dependent manner. Interestingly, in the absence of IL-1beta/Fk stimulation and the lack of sPLA2-IIA protein expression, all Rho inhibitors exert a small but significant increase in PGE2 formation suggesting that additional PLA2s or downstream enzymes like cyclooxygenases or prostaglandin synthases may be activated by Rho inhibitors. Western blot analyses of toxin A-, Y27632- and lovastatin-stimulated cells reveal that the cytosolic group IV PLA2 (cPLA2) and the cytosolic PGE2 synthase (cPGES), but not the sPLA2-IIA, cyclooxygenase-2 or the microsomal PGE2 synthase (mPGES), are upregulated compared to unstimulated cells. Furthermore, the Rho inhibitors induced arachidonic acid release from intact cells which is blocked by the cPLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP). In summary, these data show that inhibition of the small G-protein Rho, either by toxin A, lovastatin, or Y27632, exert a dual effect on mesangial cells: (i) in the absence of an inflammatory stimulus it activates the constitutive cPLA2 and cPGE2 synthase and generates low amount of PGE2. (ii) In the presence of inflammatory cytokines it potentiates sPLA2-IIA expression and subsequent PGE2 formation. In addition, we identified lovastatin and Y27632 as direct inhibitors of sPLA2-IIA in a cell-free system.
Petry
Claudia
C
Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany.
Fritz
Gerhard
G
Pfeilschifter
Josef
J
Huwiler
Andrea
A
D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis*; D005920:Glomerular Mesangium / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D007375:Interleukin-1 / Q000494:pharmacology*; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D051381:Rats; D020741:rho GTP-Binding Proteins / Q000037:antagonists & inhibitors*
D007375:Interleukin-1; D005576:Colforsin; D010741:Phospholipases A; D054467:Phospholipases A2; D020741:rho GTP-Binding Proteins; D015232:Dinoprostone